{"id":5167,"date":"2022-05-19T00:58:51","date_gmt":"2022-05-19T00:58:51","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=5167"},"modified":"2023-08-29T17:54:08","modified_gmt":"2023-08-29T17:54:08","slug":"argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=5167","title":{"rendered":"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c"},"content":{"rendered":"

\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002<\/p>\n

\u8fd9\u9879\u57fa\u4e8e\u556e\u9f7f\u52a8\u7269\u7684\u7814\u7a76\u5bf9\u4e8e\u786e\u5b9a\u836f\u7269\u5982\u4f55\u88ab\u4eba\u4f53\u5438\u6536\u3001\u5206\u5e03\u3001\u4ee3\u8c22\u548c\u6392\u6cc4\u81f3\u5173\u91cd\u8981\uff0c\u5e76\u6709\u52a9\u4e8e\u4e3a 1 \u671f\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\u5efa\u7acb\u9002\u5f53\u7684\u7ed9\u836f\u65b9\u6848\u3002<\/p>\n

\u751f\u6210\u7684\u6570\u636e\u663e\u793a ARG-007 \u5728 0.05 \u6beb\u514b\/\u5343\u514b\u81f3 5 \u6beb\u514b\/\u5343\u514b\u7684\u5242\u91cf\u8303\u56f4\u5185\u5177\u6709\u826f\u597d\u7684 PK \u66f2\u7ebf\uff0c\u5305\u62ec\u7ea6 1 \u6beb\u514b\/\u5343\u514b\u81f3 3 \u6beb\u514b\/\u5343\u514b\u7684\u6709\u6548\u5242\u91cf\u8303\u56f4\uff08\u556e\u9f7f\u52a8\u7269\uff09\u3002<\/p>\n

\u836f\u7269\u5728\u8840\u6db2\u4e2d\u8fc5\u901f\u8fbe\u200b\u200b\u5230\u6700\u5927\u6d53\u5ea6\uff0c\u8868\u660e\u6cbb\u7597\u6548\u679c\u8d77\u6548\u5feb\u3002<\/p>\n

\u8bd5\u9a8c\u7814\u7a76<\/h2>\n

\u7ed3\u679c\u8bc1\u5b9e\u4e86 ARG-007 \u7684 PK \u66f2\u7ebf\uff0c\u8be5\u66f2\u7ebf\u7531 2021 \u5e74\u4e2d\u671f\u7684\u4e34\u5e8a\u524d PK \u8bd5\u70b9\u7814\u7a76\u786e\u5b9a\u3002<\/p>\n

\u5b83\u8fdb\u4e00\u6b65\u652f\u6301\u4e86\u653e\u5c04\u6027\u6807\u8bb0\u6b63\u7535\u5b50\u53d1\u5c04\u65ad\u5c42\u626b\u63cf (PET) \u6210\u50cf\u7814\u7a76\u7684\u5148\u524d\u6d4b\u91cf\u6570\u636e\uff0c\u663e\u793a ARG-007 \u88ab\u80be\u810f\u8fc5\u901f\u5438\u6536\uff08\u4ece\u4f53\u5185\u6e05\u9664\u80bd\u7684\u6807\u51c6\u9014\u5f84\uff09\u3002<\/p>\n

\u9664\u4e86\u6d4b\u91cf\u7684 PK \u6570\u636e\u5916\uff0c\u5728\u7814\u7a76\u7684\u6bcf\u4e2a\u7ec4\u7684\u52a8\u7269\u4e2d\u90fd\u6ca1\u6709\u89c2\u5bdf\u5230\u4e0d\u826f\u53cd\u5e94\u3002<\/p>\n

\u6570\u636e\u8868\u660e\uff0c\u5728\u836f\u6548\u5b66\u76f8\u5173\u5242\u91cf\u4e0b\uff0cARG-007 \u5728\u4eba\u4f53\u4e2d\u5e94\u8be5\u662f\u5b89\u5168\u4e14\u8010\u53d7\u826f\u597d\u7684\u3002<\/p>\n

\u8d44\u6599\u5305<\/h2>\n

\u4e86\u89e3\u7814\u7a76\u836f\u7269\u7684 PK \u5bf9\u4e8e\u5efa\u7acb\u9002\u5f53\u7684\u7ed9\u836f\u65b9\u6848\u81f3\u5173\u91cd\u8981\uff0c\u5e76\u4e14\u662f\u542f\u52a8 ARG-007 \u4e34\u5e8a\u5f00\u53d1\u6240\u9700\u7684\u6570\u636e\u5305\u7684\u91cd\u8981\u7ec4\u6210\u90e8\u5206\u3002<\/p>\n

\u9996\u5e2d\u6267\u884c\u5b98 Liz Dallimore \u535a\u58eb\u8868\u793a\uff0c\u8fd9\u4e9b\u6570\u636e\u5c06\u7528\u4e8e\u66f4\u6709\u6548\u5730\u89c4\u5212 1 \u671f\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/p>\n

\u201c\u8fd9\u9879\u836f\u4ee3\u52a8\u529b\u5b66\u7814\u7a76\u7684\u5b8c\u6210\u662f\u5b8c\u6210\u6211\u4eec\u7684\u4f26\u7406\u63d0\u4ea4\u6240\u9700\u7684\u6700\u540e\u4e00\u6b65\uff0c\u4f7f\u6211\u4eec\u80fd\u591f\u66f4\u63a5\u8fd1\u542f\u52a8\u6211\u4eec\u7684 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u201d\u5979\u8bf4\u3002<\/p>\n

\u201c\u5728\u8fd9\u9879\u52a8\u7269\u7814\u7a76\u4e2d\u83b7\u5f97\u6709\u5229\u7684 PK \u66f2\u7ebf\u8865\u5145\u4e86\u6211\u4eec\u4ece\u5b89\u5168\u548c\u6bd2\u7406\u5b66\u7814\u7a76\u4e2d\u83b7\u5f97\u7684\u79ef\u6781\u6570\u636e\u3002\u201d<\/p>\n

\u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c<\/h2>\n

1 \u671f\u8bd5\u9a8c\u65e8\u5728\u63d0\u9ad8 Argenica \u5bf9 ARG-007 \u5982\u4f55\u5f71\u54cd\u8eab\u4f53\u7684\u7406\u89e3\uff0c\u5e76\u4f7f\u5176\u80fd\u591f\u8bc4\u4f30\u8be5\u836f\u7269\u5728\u4eba\u4f53\u4e2d\u7684\u5b89\u5168\u6027\u3002<\/p>\n

\u5b83\u8fd8\u5c06\u4e13\u6ce8\u4e8e\u786e\u5b9a\u7406\u60f3\u7684\u5b89\u5168\u5242\u91cf\u5e76\u5728\u516c\u53f8\u8fdb\u5165\u66f4\u5168\u9762\u7684 2 \u671f\u8bd5\u9a8c\u4e4b\u524d\u786e\u5b9a\u4efb\u4f55\u53ef\u80fd\u7684\u4e0d\u826f\u53cd\u5e94\uff0c\u5176\u4e2d ARG-007 \u5c06\u7528\u4e8e\u4e2d\u98ce\u60a3\u8005\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002 \u8fd9\u9879\u57fa\u4e8e\u556e\u9f7f\u52a8\u7269\u7684\u7814\u7a76\u5bf9\u4e8e\u786e\u5b9a\u836f\u7269\u5982\u4f55\u88ab\u4eba\u4f53\u5438\u6536\u3001\u5206\u5e03\u3001\u4ee3\u8c22\u548c\u6392\u6cc4\u81f3\u5173\u91cd\u8981\uff0c\u5e76\u6709\u52a9\u4e8e\u4e3a 1 \u671f\u4eba\u4f53\u4e34\u5e8a\u8bd5\u9a8c\u5efa\u7acb\u9002\u5f53\u7684\u7ed9\u836f\u65b9\u6848\u3002 \u751f\u6210\u7684\u6570\u636e\u663e\u793a ARG-007 \u5728 0.05 \u6beb\u514b\/\u5343\u514b\u81f3 5 \u6beb\u514b\/\u5343\u514b\u7684\u5242\u91cf\u8303\u56f4\u5185\u5177\u6709\u826f\u597d\u7684 PK \u66f2\u7ebf\uff0c\u5305\u62ec\u7ea6 1 \u6beb\u514b\/\u5343\u514b\u81f3 3 \u6beb\u514b\/\u5343\u514b\u7684\u6709\u6548\u5242\u91cf\u8303\u56f4\uff08\u556e\u9f7f\u52a8\u7269\uff09\u3002 \u836f\u7269\u5728\u8840\u6db2\u4e2d\u8fc5\u901f\u8fbe\u200b\u200b\u5230\u6700\u5927\u6d53\u5ea6\uff0c\u8868\u660e\u6cbb\u7597\u6548\u679c\u8d77\u6548\u5feb\u3002 \u8bd5\u9a8c\u7814\u7a76 \u7ed3\u679c\u8bc1\u5b9e\u4e86 ARG-007 \u7684 PK \u66f2\u7ebf\uff0c\u8be5\u66f2\u7ebf\u7531 2021 \u5e74\u4e2d\u671f\u7684\u4e34\u5e8a\u524d PK \u8bd5\u70b9\u7814\u7a76\u786e\u5b9a\u3002 \u5b83\u8fdb\u4e00\u6b65\u652f\u6301\u4e86\u653e\u5c04\u6027\u6807\u8bb0\u6b63\u7535\u5b50\u53d1\u5c04\u65ad\u5c42\u626b\u63cf (PET) \u6210\u50cf\u7814\u7a76\u7684\u5148\u524d\u6d4b\u91cf\u6570\u636e\uff0c\u663e\u793a ARG-007 \u88ab\u80be\u810f\u8fc5\u901f\u5438\u6536\uff08\u4ece\u4f53\u5185\u6e05\u9664\u80bd\u7684\u6807\u51c6\u9014\u5f84\uff09\u3002 \u9664\u4e86\u6d4b\u91cf\u7684 PK \u6570\u636e\u5916\uff0c\u5728\u7814\u7a76\u7684\u6bcf\u4e2a\u7ec4\u7684\u52a8\u7269\u4e2d\u90fd\u6ca1\u6709\u89c2\u5bdf\u5230\u4e0d\u826f\u53cd\u5e94\u3002 \u6570\u636e\u8868\u660e\uff0c\u5728\u836f\u6548\u5b66\u76f8\u5173\u5242\u91cf\u4e0b\uff0cARG-007 \u5728\u4eba\u4f53\u4e2d\u5e94\u8be5\u662f\u5b89\u5168\u4e14\u8010\u53d7\u826f\u597d\u7684\u3002 \u8d44\u6599\u5305 \u4e86\u89e3\u7814\u7a76\u836f\u7269\u7684 PK \u5bf9\u4e8e\u5efa\u7acb\u9002\u5f53\u7684\u7ed9\u836f\u65b9\u6848\u81f3\u5173\u91cd\u8981\uff0c\u5e76\u4e14\u662f\u542f\u52a8 ARG-007 \u4e34\u5e8a\u5f00\u53d1\u6240\u9700\u7684\u6570\u636e\u5305\u7684\u91cd\u8981\u7ec4\u6210\u90e8\u5206\u3002 \u9996\u5e2d\u6267\u884c\u5b98 Liz Dallimore… Continue reading Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":13742,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[888],"yoast_head":"\nArgenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c<\/title>\n<meta name=\"description\" content=\"\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c\" \/>\n<meta property=\"og:description\" content=\"\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-19T00:58:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:54:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Argenica-Therapeutics-ASX-AGN-pre-clinical-results-stroke-drug-ARG-007-HIE-hypoxic-ischaemic-encephalopathy-brain-tissue.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/\",\"name\":\"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-05-19T00:58:51+00:00\",\"dateModified\":\"2023-08-29T17:54:08+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c","description":"\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c","og_description":"\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/","og_site_name":"smallcapsCN","article_published_time":"2022-05-19T00:58:51+00:00","article_modified_time":"2023-08-29T17:54:08+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Argenica-Therapeutics-ASX-AGN-pre-clinical-results-stroke-drug-ARG-007-HIE-hypoxic-ischaemic-encephalopathy-brain-tissue.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/","url":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/","name":"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-05-19T00:58:51+00:00","dateModified":"2023-08-29T17:54:08+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u603b\u90e8\u4f4d\u4e8e\u73c0\u65af\u7684\u751f\u7269\u6280\u672f\u516c\u53f8 Argenica Therapeutics (ASX: AGN) \u5df2\u5b8c\u6210\u5173\u4e8e\u4e3b\u8981\u5019\u9009\u836f\u7269 ARG-007\u5bf9\u4e2d\u98ce\u60a3\u8005\u8eab\u4f53\u529f\u80fd\u5f71\u54cd\u7684\u6700\u7ec8\u836f\u4ee3\u52a8\u529b\u5b66 (PK) \u7814\u7a76\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/argenica-therapeutics-moves-closer-phase-1-human-trials-arg-007-stroke\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Argenica Therapeutics \u63a5\u8fd1 ARG-007 \u7528\u4e8e\u4e2d\u98ce\u7684 1 \u671f\u4eba\u4f53\u8bd5\u9a8c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5167"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5167"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5167\/revisions"}],"predecessor-version":[{"id":15046,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5167\/revisions\/15046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/13742"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}